| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | 0 |
Sells | $3,762,865 | 5 | 100 |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 0 | $0 | 5 | $3.76M | $-3.76M |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Over the last 12 months, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $0 and sold $3.76M worth of Acrivon Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Acrivon Therapeutics, Inc. Common Stock have bought $33.68M and sold $1.93M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,353,000 shares for transaction amount of $20M was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑11.
| 2025-05-01 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 298,886 0.9604% | $1.34 | $400,507 | -11.85% | |
| 2025-04-30 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 437,881 1.4067% | $1.41 | $617,412 | -18.71% | |
| 2025-04-29 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 250,000 0.7808% | $1.41 | $352,500 | -15.37% | |
| 2025-04-28 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 215,283 0.6532% | $1.56 | $335,841 | -19.87% | |
| 2025-04-25 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 1.05M 3.9999% | $1.95 | $2.06M | -29.03% | |
| 2024-04-11 | PERCEPTIVE ADVISORS LLC | 10 percent owner | 2.35M 8.4743% | $8.50 | $20M | -22.39% | ||
| 2023-06-26 | Sale | Chione Ltd | 10 percent owner | 16 <0.0001% | $12.93 | $207 | -48.66% | |
| 2023-06-15 | Sale | Chione Ltd | 10 percent owner | 2,056 0.0106% | $12.14 | $24,960 | -39.33% | |
| 2023-06-14 | Sale | Chione Ltd | 10 percent owner | 893 0.0046% | $12.13 | $10,832 | -38.40% | |
| 2023-06-13 | Sale | Chione Ltd | 10 percent owner | 3,000 0.0156% | $12.30 | $36,900 | -40.28% | |
| 2023-06-12 | Sale | Chione Ltd | 10 percent owner | 2,000 0.0105% | $12.34 | $24,680 | -40.91% | |
| 2022-11-17 | RA CAPITAL MANAGEMENT, L.P. | 3.39M 17.9519% | $12.50 | $42.37M | -21.95% | |||
| 2022-11-17 | Chione Ltd | 10 percent owner | 400,000 2.1185% | $12.50 | $5M | -21.95% |
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 3104139 9.8999% | $3.63M | 1 | 5 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 4384206 13.9823% | $5.13M | 1 | 0 | <0.0001% | |
| Chione Ltd | 10 percent owner | 3848632 12.2742% | $4.5M | 1 | 5 | <0.0001% |
$12,784,645 | 193 | 20.49% | $40.32M | |
$155,580,641 | 77 | -24.21% | $35.49M | |
$14,315,062 | 61 | -6.21% | $33.84M | |
$459,011,221 | 33 | 33.04% | $43.91M | |
$47,863,113 | 17 | -22.07% | $41.99M | |
$36,557,692 | 17 | 3.38% | $35.31M | |
$20,234,041 | 17 | 2.09% | $39.66M | |
$1,044,754 | 13 | -23.07% | $45.3M | |
$232,423 | 8 | 14.22% | $43.52M | |
$22,090,972 | 7 | -3.49% | $38.93M | |
$149,996 | 5 | 16.26% | $37.27M | |
$147,504 | 5 | -36.70% | $29.01M | |
$26,254,149 | 5 | 49.97% | $33.63M | |
$1,446,995 | 5 | -3.03% | $33.34M | |
$657,791 | 4 | -52.05% | $38.58M | |
Acrivon Therapeutics, Inc. Common Stock (ACRV) | $67,369,250 | 3 | -22.09% | $36.69M |
$26,374 | 2 | -53.61% | $32.29M | |
$100,266 | 2 | 3.17% | $29.96M | |
$150,000 | 1 | 5.48% | $35.48M |
| Increased Positions | 23 | +30.26% | 149,922 | +0.64% |
| Decreased Positions | 30 | -39.47% | 898,083 | -3.86% |
| New Positions | 7 | New | 76,996 | New |
| Sold Out Positions | 8 | Sold Out | 162,986 | Sold Out |
| Total Postitions | 69 | -9.21% | 23M | -3.22% |
| Ra Capital Management, L.P. | $11,760.00 | 26.91% | 8.34M | 0 | 0% | 2024-12-31 |
| Perceptive Advisors Llc | $7,559.00 | 17.29% | 5.36M | 0 | 0% | 2024-12-31 |
| Sands Capital Ventures, Llc | $2,993.00 | 6.85% | 2.12M | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $2,989.00 | 6.84% | 2.12M | -20,982 | -0.98% | 2024-12-31 |
| Blackrock, Inc. | $1,324.00 | 3.03% | 938,707 | -6,789 | -0.72% | 2025-03-31 |
| Wellington Management Group Llp | $1,252.00 | 2.87% | 888,130 | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $947.00 | 2.17% | 671,625 | +34,087 | +5.35% | 2024-12-31 |
| Marshall Wace, Llp | $843.00 | 1.93% | 597,794 | -212,065 | -26.18% | 2024-12-31 |
| Acorn Capital Advisors, Llc | $571.00 | 1.31% | 405,237 | +405,237 | New | 2024-12-31 |
| Geode Capital Management, Llc | $425.00 | 0.97% | 301,389 | -714 | -0.24% | 2024-12-31 |